Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2023
‘Enough sickness’ to share GP load among pharmacists, nurses
2 February 2023 - Pharmacy Guild of Australia president Trent Twomey says there is enough “demand and sickness” to allow ...
Posted by Michael Wonder on 31 Jan 2023
FDA may not always require post-approval trials to be enrolled before accelerated approvals
30 January 2023 - A FDa official on Monday gave more clues for how the agency plans to wield new authority ...
Posted by Michael Wonder on 31 Jan 2023
Options for a reformed Prostheses List pre-listing assessment framework and governance structure
31 January 2023 - This report provides a framework and proposes options for governance that would align the Prostheses List processes ...
Posted by Michael Wonder on 26 Jan 2023
Draft methods (version 7.0): IQWiG is extending the comment period
26 January 2023 - The new deadline is 28 February 2023. ...
Posted by Michael Wonder on 25 Jan 2023
The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals
25 January 2023 - Congress just boosted the FDA’s authority over the post-market clinical trials that are a condition of ...
Posted by Michael Wonder on 24 Jan 2023
Reform Medicare to sustain system
25 January 2023 - Australia’s hybrid public/private healthcare system, including the principle of universal coverage through Medicare, has served the nation ...
Posted by Michael Wonder on 20 Jan 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee
20 January 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee held its first two meetings on 1 ...
Posted by Michael Wonder on 20 Jan 2023
Consultation on the revised PBS post-market review framework – publication of responses
20 January 2023 - Consultation on a revised draft of the PBS post-market review framework was open from 20 October ...
Posted by Michael Wonder on 18 Jan 2023
FDA’s breakthrough program: faster drug OKs without sacrificing safety
18 January 2023 - A FDA program markedly cut the time and cost of bringing to market new drugs, without ...
Posted by Michael Wonder on 15 Jan 2023
PHARMAC's year in review leaves much to be desired
1 January 2023 - Christmas came early for a number of long-suffering patients. ...
Posted by Michael Wonder on 11 Jan 2023
Prescription drug policy, 2022 and 2023: the year in review and the year ahead
9 January 2023 - This past year featured many significant developments in the prescription drug policy area, most notably the passage ...
Posted by Michael Wonder on 21 Nov 2022
FDA cancer chief wants quicker ways to pull failed drugs
17 November 2022 - Makena highlights need to make system more nimble. ...
Posted by Michael Wonder on 18 Nov 2022
Medicines industry calls for discount rate reduction now
18 November 2022 - Medicines Australia welcomes the recommendation to lower the discount rate for medicines and vaccines but questions ...
Posted by Michael Wonder on 06 Nov 2022
Independent review into Medicare compliance
5 November 2022 - The Albanese Government has appointed respected health economist Dr Pradeep Philip to conduct an independent review into ...
Posted by Michael Wonder on 27 Oct 2022
Health technology assessment review – frequently asked questions
27 October 2022 - The Department of Health & Aged Care has produced a two page summary on the upcoming ...